2024
The combination of CDX2 expression status and tumor-infiltrating lymphocyte density as a prognostic factor in adjuvant FOLFOX-treated patients with stage III colorectal cancers
Lee J, Park H, Jin H, Jin L, Yoo S, Cho N, Bae J, Kim J, Kang G. The combination of CDX2 expression status and tumor-infiltrating lymphocyte density as a prognostic factor in adjuvant FOLFOX-treated patients with stage III colorectal cancers. Journal Of Pathology And Translational Medicine 2024, 59: 50-59. PMID: 39440351, PMCID: PMC11736276, DOI: 10.4132/jptm.2024.09.26.Peer-Reviewed Original ResearchTumor-infiltrating lymphocytesCaudal-type homeobox 2CD8 tumor-infiltrating lymphocytesTumor-infiltrating lymphocyte densitySurvival of patientsColorectal carcinomaStromal areaClinical outcomesHigh density of tumor-infiltrating lymphocytesDensity of tumor-infiltrating lymphocytesAdjuvant chemotherapy-treated patientsStage III colorectal carcinomaStage III colorectal cancerFOLFOX-treated patientsCancer-specific survivalChemotherapy-treated patientsIII colorectal carcinomaIII colorectal cancerTIL densityPrognostic factorsPrognostic parametersLymphocyte densityPrognostic markerCDX2 expressionColorectal cancer
2021
Utility of the 21-Gene Recurrence Score in Node-Positive Breast Cancer.
Laws A, Garrido-Castro A, Poorvu P, Winer E, Mittendorf E, King T. Utility of the 21-Gene Recurrence Score in Node-Positive Breast Cancer. Oncology 2021, 35: 77-84. PMID: 33577165, DOI: 10.46883/onc.2021.3502.0077.Peer-Reviewed Original ResearchConceptsRecurrence scorePositive nodesClinical trialsBreast cancerHER2-negative breast cancerNode-positive breast cancerLarge population-based registryNode-positive populationAdjuvant chemotherapy useChemotherapy-treated patientsClinical practice guidelinesCurrent practice patternsPopulation-based registryMultiple clinical trialsPotential predictive valueADAPT trialAdjuvant chemotherapyChemotherapy useEndocrine therapyPostmenopausal patientsChemotherapy benefitExcellent outcomesPractice patternsPractice guidelinesRetrospective analysisCytoreductive Surgery for Selected Patients Whose Metastatic Gastric Cancer was Treated with Systemic Chemotherapy
Berger Y, Giurcanu M, Vining C, Schuitevoerder D, Posner M, Roggin K, Polite B, Liao C, Eng O, Catenacci D, Turaga K. Cytoreductive Surgery for Selected Patients Whose Metastatic Gastric Cancer was Treated with Systemic Chemotherapy. Annals Of Surgical Oncology 2021, 28: 4433-4443. PMID: 33420565, DOI: 10.1245/s10434-020-09475-6.Peer-Reviewed Original ResearchConceptsMetastatic gastric adenocarcinomaNational Cancer DatabaseSystemic chemotherapyCytoreductive surgeryMedian OSOverall survivalTreated with systemic chemotherapyChemotherapy-treated patientsMetastatic gastric cancerKaplan-Meier analysisPropensity-matched patientsCox regression modelsOS periodsOS benefitPropensity score matchingCancer DatabaseNo surgeryGastric adenocarcinomaBackgroundThe authorsGastric cancerHazard ratioProportion of diseaseM1 stageChemotherapyPatients
2020
Cytoreductive surgery in selected patients with metastatic gastric cancer treated with systemic chemotherapy.
Berger Y, Schuitevoerder D, Vining C, Giurcanu M, Posner M, Roggin K, Polite B, Liao C, Eng O, Catenacci D, Turaga K. Cytoreductive surgery in selected patients with metastatic gastric cancer treated with systemic chemotherapy. Journal Of Clinical Oncology 2020, 38: 409-409. DOI: 10.1200/jco.2020.38.4_suppl.409.Peer-Reviewed Original ResearchMetastatic gastric adenocarcinomaNational Cancer DatabaseSystemic chemotherapyOverall survivalMedian OSCytoreductive surgeryNo surgeryGastric adenocarcinomaChemotherapy-treated patientsCompared to patientsKaplan-Meier analysisClinically occult diseaseGroup of patientsCox regression modelsOS benefitTumor burdenOccult diseaseCancer DatabaseTumor-relatedImproved survivalMatched CohortChemotherapyHazard ratioProportion of diseaseM1 stage
2016
Effectiveness of Adjuvant Chemotherapy for Locally Advanced Bladder Cancer
Galsky M, Stensland K, Moshier E, Sfakianos J, McBride R, Tsao C, Casey M, Boffetta P, Oh W, Mazumdar M, Wisnivesky J. Effectiveness of Adjuvant Chemotherapy for Locally Advanced Bladder Cancer. Journal Of Clinical Oncology 2016, 34: 825-832. PMID: 26786930, DOI: 10.1200/jco.2015.64.1076.Peer-Reviewed Original ResearchConceptsLocally advanced bladder cancerEffect of adjuvant chemotherapyAdjuvant chemotherapyBladder cancerOverall survivalPerformance statusImproved survivalNode-positive bladder cancerNational Cancer Data BaseAssociated with improved survivalObservational studyEffect of cystectomyTumor-level characteristicsImpact of performance statusPositive surgical marginsChemotherapy-treated patientsCompare overall survivalLymph node involvementAdvanced bladder cancerPoor performance statusLevel I evidencePropensity scoreReal-world patientsStudy inclusion criteriaPathological T3
2005
Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib
Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, Ince WL, Jänne PA, Januario T, Johnson DH, Klein P, Miller VA, Ostland MA, Ramies DA, Sebisanovic D, Stinson JA, Zhang YR, Seshagiri S, Hillan KJ. Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib. Journal Of Clinical Oncology 2005, 23: 5900-5909. PMID: 16043828, DOI: 10.1200/jco.2005.02.857.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCarcinoma, Non-Small-Cell LungCombined Modality TherapyDNA Mutational AnalysisErbB ReceptorsErlotinib HydrochlorideFemaleGenes, rasHumansLung NeoplasmsMaleMiddle AgedPaclitaxelPlacebosPredictive Value of TestsPrognosisQuinazolinesSurvival AnalysisTreatment OutcomeConceptsRetrospective subset analysisCell lung cancerEGFR mutationsKRAS mutationsLung cancerSubset analysisSingle-agent EGFR inhibitorsEpidermal growth factor receptor (EGFR) mutationsEGFR inhibitorsErlotinib-treated patientsFirst-line chemotherapyAdvanced NSCLC patientsChemotherapy-treated patientsPositive prognostic factorPoor clinical outcomeEGFR inhibitor treatmentImproved response ratesKRAS-mutant NSCLCKRAS exon 2Epidermal growth factor receptorGrowth factor receptorAdvanced NSCLCUntreated patientsNSCLC patientsPrognostic factors
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply